United States Food and Drug Administration (USFDA) has granted approval to UK-based Circassia Pharmaceuticals' DUAKLIR PRESSAIR (aclidinium bromide and formoterol fumarate) product for the treatment of chronic obstructive pulmonary disease, it was reported yesterday.

The product is a fixed-dose LAMA/LABA combination of the long-acting muscarinic antagonist (LAMA) aclidinium and the long-acting beta agonist (LABA) formoterol, administered via a PRESSAIR multi-dose inhaler. The product is approved globally, including in the European Union, under various brand names.

David Acheson, Senior Vice President, US Commercial, Circassia, said, 'Our collaboration with AstraZeneca throughout the DUAKLIR PRESSAIR regulatory process has been overwhelmingly positive. We look forward to bringing DUAKLIR PRESSAIR to market in the coming months as an important expansion of Circassia's COPD and respiratory health portfolio.'